EGFR and non-small cell lung carcinoma: In our study, through the analysis of matched primary and post-operative recurrence in 45 patients, we observed two key findings: first, temporal genetic heterogeneity occurred relatively commonly between the primary and post-operative recurrent NSCLC tumors; Second, temporal heterogeneity might influence the therapeutic efficacy of first-line EGFR TKI treatment at relapse.